CLCA2 as a Novel Immunohistochemical Marker for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung

Table 4

CLCA2 protein expression status and clinicopathological factors in 161 patients with primary squamous cell carcinoma of the lung.

Factor	Number of patients	CLCA2 protein expression status by IHC analysis
		Positive (n = 104)	Negative (n = 57)	P value
Gender
Female	31	22 (71.0%)	9 (29.0%)	0.4091^b
Male	130	82 (63.1%)	48 (36.9%)
Age
<60	29	16 (55.2%)	13 (44.8%)	0.2412^b
60	132	88 (66.7%)	44 (33.3%)
Average ± SD^a	67.2 ± 8.7	68.0 ± 7.9	65.7 ± 10.0	0.1098^c
Grading
G1 or G2	115	86 (74.8%)	29 (25.2%)	<0.0001^b
G3	46	18 (39.1%)	28 (60.9%)
pT stage
pT1	44	30 (68.1%)	14 (31.8%)	0.5596^b
pT2–pT4	117	74 (63.3%)	43 (36.7%)
pN stage
pN0	97	66 (68.0%)	31 (32.0%)	0.3712^b
pN1–pN3	59	36 (61.0%)	23 (39.0%)

SD: standard deviation. ^bChi-square test. -test.